Please use this identifier to cite or link to this item: https://doi.org/10.1111/bpa.12631
Title: Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration
Authors: Chai, Yuek Ling 
Chong, Joyce R 
Weng, Jiaju
Howlett, David
Halsey, Andrea
Lee, Jasinda H 
Attems, Johannes
Aarsland, Dag
Francis, Paul T
Chet, Christopher P
Lai, Mitchell K 
Keywords: Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Pathology
Neurosciences & Neurology
Alzheimer's disease
cathepsin D
Lewy body dementia
lysosome
neurofibrillary degeneration
AMYLOID PRECURSOR PROTEIN
A-BETA-DEPOSITION
LEWY BODIES
NEUROPATHOLOGIC ASSESSMENT
PARKINSON-DISEASE
ALPHA-SYNUCLEIN
PROCATHEPSIN-D
CELL-CYCLE
DEMENTIA
TAU
Issue Date: 1-Jan-2019
Publisher: WILEY
Citation: Chai, Yuek Ling, Chong, Joyce R, Weng, Jiaju, Howlett, David, Halsey, Andrea, Lee, Jasinda H, Attems, Johannes, Aarsland, Dag, Francis, Paul T, Chet, Christopher P, Lai, Mitchell K (2019-01-01). Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. BRAIN PATHOLOGY 29 (1) : 63-74. ScholarBank@NUS Repository. https://doi.org/10.1111/bpa.12631
Abstract: Alzheimer's disease (AD) is characterized by accumulation of β-amyloid plaques (AP) and neurofibrillary tangles (NFT) in the cortex, together with synaptic loss and amyloid angiopathy. Perturbations in the brain lysosomal system, including the cathepsin family of proteases, have been implicated in AD where they may be involved in proteolytic clearance of misfolded and abnormally aggregated peptides. However, the status of cathepsin D (catD) is unclear in Lewy body dementia, the second most common form of neurodegenerative dementia after AD, and characterized by Lewy bodies (LB) containing aggregated α-synuclein. Furthermore, earlier reports of catD changes in AD have not been entirely consistent. We measured CatD immunoreactivities in the temporal (Brodmann area BA21) and parietal (BA40) cortices of well characterized AD brains as well as two clinical subtypes of Lewy body dementia, namely Parkinson disease dementia (PDD) and dementia with Lewy bodies (DLB), known to show varying degrees of concomitant AD pathology. Increased catD immunoreactivities in AD were found for both neocortical regions measured, where they also correlated with neuropathological NFT scores and phosphorylated pSer396 tau burden, and appeared to co-localize at least partly to NFT-containing neurons. In contrast, catD was increased only in BA40 in DLB and not at all in PDD, did not correlate with LB scores, and did not appreciably co-localize with α-synuclein inclusions. Our study suggests that catD upregulation may be an adaptive response to AD-related processes leading to neurofibrillary degeneration, but may not be directly associated with formation of α-synuclein inclusions in Lewy body dementia.
Source Title: BRAIN PATHOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/188360
ISSN: 10156305
17503639
DOI: 10.1111/bpa.12631
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
64 Chai Weng CatD AD BDR BPATH 2019.pdf706.9 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

22
checked on Jan 21, 2022

Page view(s)

82
checked on Jan 27, 2022

Download(s)

1
checked on Jan 27, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.